Lipoprotein-associated phospholipase A2: A new therapeutic target

被引：4
|
作者：
Lonn, Eva [1 ]
机构：
[1] McMaster Univ, Hamilton Hlth Sci & Populat Hlth Res Inst, Hamilton, ON, Canada
来源：
CANADIAN JOURNAL OF CARDIOLOGY | 2010年 / 26卷
关键词：
Atherosclerosis; Inflammation; Lipoprotein-associated phospholipase A(2); Plaque rupture; CORONARY-ARTERY-DISEASE; ACTIVATING-FACTOR-ACETYLHYDROLASE; C-REACTIVE PROTEIN; MIDDLE-AGED MEN; FUTURE CARDIOVASCULAR EVENTS; LOW-DENSITY-LIPOPROTEIN; HEART-DISEASE; ISCHEMIC-STROKE; RISK-FACTORS; ENDOTHELIAL DYSFUNCTION;
D O I：
10.1016/S0828-282X(10)71058-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Lipoprotein-associated phospholipase A(2) is in enzyme produced by inflammatory cells, which binds to apolipoprotein B-containing lipoproteins and degrades oxidatively modified phospholipids in low-density lipoprotein cholesterol pail-iciest leading to formation of proinflammatory and cytotoxic products. Experimental studies suggest a role for lipoprotein-associated phospholipase A(2) in the formation of advanced rupture-prone artherosclerotic lesions, and epidemiological investigations have linked it to increased cardiovascular risk. Ongoing trials are evaluating the role of novel pharmacological inhibitors of this enzyme, such its darapladib, in the management or high-risk coronary artery disease patients.
引用
收藏
页码：27A / 31A
页数：5
相关论文
共 50 条
  • [31] Lipoprotein-associated phospholipase A2 (Lp-PLA2): Relevant biomarker and therapeutic target?
    Bonnefont-Rousselot, Dominique
    ANNALES PHARMACEUTIQUES FRANCAISES, 2025, 83 (01): : 45 - 57
  • [32] Racial variation in lipoprotein-associated phospholipase A2 in older adults
    Lee, Keane K.
    Fortmann, Stephen P.
    Varady, Ann
    Fair, Joan M.
    Go, Alan S.
    Quertermous, Thomas
    Hlatky, Mark A.
    Iribarren, Carlos
    BMC CARDIOVASCULAR DISORDERS, 2011, 11
  • [33] The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice
    Hu, Miao-miao
    Zhang, Jie
    Wang, Wen-yi
    Wu, Wen-yu
    Ma, Yan-ling
    Chen, Wei-hai
    Wang, Yi-ping
    ACTA PHARMACOLOGICA SINICA, 2011, 32 (10) : 1253 - 1258
  • [34] Elevated Lipoprotein-Associated Phospholipase A2 Is Associated with Progression of Nonculprit Lesions after Percutaneous Coronary Intervention
    Xin, Hui
    Gong, Hui-Ping
    Cai, Shang-Lang
    Ning, Xian-Feng
    Liu, Song
    Chen, Zuo-Yuan
    Lian, Zhe-Xun
    Zhang, Rui
    Zhang, Quan-Fang
    Kang, Wei-Qiang
    Ge, Zhi-Ming
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2013, 230 (02) : 97 - 102
  • [35] Lipoprotein associated phospholipase A2 as a target of therapy
    Macphee, CH
    Nelson, JJ
    Zalewski, A
    CURRENT OPINION IN LIPIDOLOGY, 2005, 16 (04) : 442 - 446
  • [36] Influence of Intensive Hypolipidemic Therapy on Blood Concentration of Lipoprotein-Associated Phospholipase A2 in Patients With Ischemic Heart Disease
    Miklishanskaya, S. V.
    Vlasik, T. N.
    Kheimets, G. I.
    Kaznacheeva, E. I.
    Lyakishev, A. A.
    Kukharchuk, V. V.
    KARDIOLOGIYA, 2013, 53 (09) : 4 - +
  • [37] Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease
    Hatoum, Ida J.
    Nelson, Jeanenne J.
    Cook, Nancy R.
    Hu, Frank B.
    Rimm, Eric B.
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2010, 91 (03) : 786 - 793
  • [38] Correlation between plasma lipoprotein-associated phospholipase A2 and peripheral arterial disease
    Li, Shuai-Bing
    Yang, Fan
    Jing, Li
    Ma, Juan
    Jia, Ya-Dan
    Dong, Shao-Ying
    Zheng, Wei-Feng
    Zhao, Luo-Sha
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2013, 5 (05) : 1451 - 1455
  • [39] Lipoprotein-associated phospholipase A2 and venous thromboembolism: A prospective study
    Folsom, Aaron R.
    Lutsey, Pamela L.
    Roetker, Nicholas S.
    Ballantyne, Christie M.
    Hoogeveen, Ron C.
    Rosamond, Wayne D.
    Cushman, Mary
    THROMBOSIS RESEARCH, 2013, 132 (01) : 44 - 46
  • [40] Lipoprotein-Associated Phospholipase A2 as a Novel Risk Marker for Cardiovascular Disease A Systematic Review of the Literature
    Madjid, Mohammad
    Ali, Muzammil
    Willerson, James T.
    TEXAS HEART INSTITUTE JOURNAL, 2010, 37 (01): : 25 - 39
12345